Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Authors

Li Zhang

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

Li Zhang , Ping Peng , Juejun Gong , Yujie Zhang , Qian Chu , Shu Xia , Rui Meng , Yongshun Chen , Guang Han , Peng Zhang , Lu Zhang , Yuan Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

First Author: Julien Mazieres

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC.

First Author: Julien Mazières

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).

First Author: Min Hee Hong

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).

First Author: Atsushi Nakamura